April 28, 2023: Microbiome Times - FDA Lifts Hold on Maat Pharma’s Phase 3 Investigational NDA for MaaT013

Previous PostMay 3, 2023: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
Next PostApril 28, 2023: Microbiome Post - MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease

April 28, 2023: Microbiome Times – FDA Lifts Hold on Maat Pharma’s Phase 3 Investigational NDA for MaaT013